Has the Canadian Pharma Industry valuation changed over the past few years?

Investors are more pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 10.0x which is lower than its 3-year average PE of 19.0x.

How does Canadian Pharma compare with similar industries?

There is insufficient data on the sub-industries of this industry.

Canadian (TSX) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Sat, 28 May 2022	CA$32.0b	CA$12.1b	-CA$5,610,815,771.00	10x
Mon, 25 Apr 2022	CA$38.4b	CA$11.6b	-CA$4,727,983,456.00	11.3x
Wed, 23 Mar 2022	CA$43.6b	CA$11.3b	-CA$4,452,643,341.00	12.3x
Fri, 18 Feb 2022	CA$51.5b	CA$10.9b	-CA$3,875,556,557.00	14.2x
Sun, 16 Jan 2022	CA$52.5b	CA$10.4b	-CA$5,172,057,779.00	13.1x
Tue, 14 Dec 2021	CA$53.6b	CA$10.9b	-CA$4,818,365,024.00	13.9x
Thu, 11 Nov 2021	CA$60.6b	CA$9.9b	-CA$4,638,633,459.00	15.4x
Sat, 09 Oct 2021	CA$65.3b	CA$10.2b	-CA$4,879,731,906.00	20.5x
Mon, 06 Sep 2021	CA$69.2b	CA$10.2b	-CA$6,624,257,163.27	22.9x
Wed, 04 Aug 2021	CA$73.7b	CA$10.2b	-CA$6,616,236,433.27	24.6x
Sat, 08 May 2021	CA$84.2b	CA$8.9b	-CA$7,574,008,271.21	25.7x
Tue, 09 Feb 2021	CA$76.4b	CA$7.0b	-CA$8,507,898,237.09	44.1x
Mon, 02 Nov 2020	CA$43.2b	CA$6.4b	-CA$10,076,007,480.76	22.5x
Thu, 06 Aug 2020	CA$40.7b	CA$5.6b	-CA$8,958,961,022.79	22.1x
Sun, 10 May 2020	CA$30.0b	CA$5.3b	-CA$6,452,422,756.95	11.1x
Sat, 01 Feb 2020	CA$41.7b	CA$4.3b	-CA$4,932,975,667.47	17x
Tue, 05 Nov 2019	CA$41.1b	CA$3.7b	-CA$2,840,123,199.30	9.4x
Fri, 09 Aug 2019	CA$62.5b	CA$2.8b	-CA$3,472,829,784.86	14.4x


CA Market	1.68%
Healthcare	0.16%
Pharma	0.49%
Pharma	0.49%

Company	Last Price	7D	1Y	Valuation
AYR.A Ayr Wellness	CA$7.90	3.9% +CA$22.5m	-78.6%	PS1x
FFNT 4Front Ventures	CA$0.92	2.2% +CA$12.8m	-41.8%	PS4.3x
HITI High Tide	CA$3.42	5.9% +CA$11.7m	-67.9%	PS1x
CRDL Cardiol Therapeutics	CA$1.62	11.7% +CA$10.5m	-51.1%	PS1275.6x
GUD Knight Therapeutics	CA$5.39	1.5% +CA$9.2m	2.5%	PS2.4x

May 27

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The Company has received positive comments from the FDA in regards to the Company’s request to determine and agree on the Study’s potential new primary efficacy endpoints, including the rate of sustained clinical resolution of symptoms of COVID-19, which addresses the shift in COVID-19 clinical outcome observed over the course of the pandemic, and, therefore, to have more meaningful study endpoints for the FDA to consider for potential Emergency Use Authorization. The FDA has agreed that the Company may unblind the pre-dose-selection data for the first 210 patients of the Study to further support the new primary endpoint. Before unblinding the pre-dose selection data for the first 210 patients, the Company will submit a Data Access Plan to the FDA in early June 2022 with the aim to unblind the pre-dose selection data and submit the amended Study protocol with the new primary efficacy endpoints to the FDA. In addition, the Data Safety and Monitoring Board (“DSMB”) are scheduled to meet thereafter to evaluate the interim clinical and safety data and may make a recommendation on continuing the Study or advise on halting the Study early due to positive efficacy based on other clinical outcomes such as the rate of sustained clinical resolution of symptoms of COVID-19. The DSMB supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported. The Company believes that with the Omicron variant, including the BA.2 variant, being the dominant strain over the Delta variant, there is an urgent unmet need to treat symptom resolutions in addition to preventing hospitalizations.

May 21

Canopy Growth Corporation unveils Line-Up of New Offerings Across Its Premium Brand Portfolio – 7ACRES, Ace Valley, Deep Space and Doja

Canopy Growth Corporation unveiled a line-up of new offerings across its premium brand portfolio – 7ACRES, Ace Valley, Deep Space and Doja. With select products releasing just in time for the first long weekend of the summer, including the release of its first large format premium flower offering for the recreational market, Doja 91K 14g, this new line-up builds on the Company's continued commitment to product innovation and meeting evolving consumer demand, while cementing Canopy's leadership position in the premium flower market. 7ACRES: 7ACRES unveiled two new premium flower offerings: 7ACRES Lemon Zkltz 3.5g, which features light green colouration with pink pistils and dense structure, pungent and complex aromas that transfer to robust flavour for a super smooth taste experience, and 7ACRES Jack Haze Bubble Hash Infused pre-roll joints. Made using a true-to-flower infusion of Jack Haze Bubble Hash, these pre-rolls deliver high potency and increased flavour for an elevated smoking experience. These products come on the heels of the Know the Grow ten-video educational content series, which provides Canadians with an inside look at the talent, genetics and grow techniques behind the 7ACRES brand and flower portfolio. Ace Valley: The Ace Valley brand portfolio continues to expand with the release of Ace Valley Wappa 3x 0.5g pre-rolled joint which comes in new recyclable and reusable packaging and boasts a pleasant, fruity aroma and flavour. Ace Valley is expanding its vape offering with Orange Frosty Live Terp Sauce 1g 510 cartridge, offering a blend of live terp sauce, extracted from fresh, flash-frozen cannabis flower, and high purity THC distillate with citrusy, sweet orange flavours that are perfect for daytime. Deep Space: In the beverage category, Deep Space released two bold new flavours: Orange Orbit and The Grape Unknown. Both full-flavoured, cannabis-infused carbonated beverages deliver a nostalgic taste with a unique flavour twist iconic to Deep Space. Fueled by 10mg of THC in every recyclable 222ml can, these new flavours are potent and ready to drink. Doja: Doja introduced three new offerings for craft cannabis connoisseurs: Doja Legendary Larry, an indica-dominant strain, hang dried and hand finished, featuring mossy green and dense buds with a layer of icy trichomes and now available as a long-term offering in 3.5g of flower and 3 x 0.5g pre-rolled joints; Doja Garlic Chem 3.5g, an indica-leaning hybrid strain available for a limited time only and influenced by the high-quality cultivation techniques found in British Columbia'sOkanagan Valley, featuring dense and colourful buds that possess a gassy and garlic combination of aromas and flavours; and Doja 91K 14g, which emits a deep, dank terpene profile that includes myrcene, linalool and limonene, and is the brand's first premium large format offering for the recreational market. These new offerings are available for purchase via legal recreational cannabis retail locations and e-commerce channels, with select products available for a limited time only, including the 7ACRES Lemon Zkltz 3.5g, Ace Valley Orange Frosty Live Terp Sauce 1g 510 cartridge and Doja Garlic Chem 3.5g.

Canadian (TSX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

TRUL

Founder recently bought CA$260k worth of stock

CL

Chief Financial Officer recently bought CA$104k worth of stock

AYR.A

Price target decreased to CA$47.88

RVV

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

TER

TerrAscend Corp. (CNSX:TER) acquired Stadium Ventures, LLC.

CURA

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

CRDL

Consensus forecasts updated

WEED

Canopy Growth Corporation unveils Line-Up of New Offerings Across Its Premium Brand Portfolio – 7ACRES, Ace Valley, Deep Space and Doja

GUD

Executive Chairman recently bought CA$207k worth of stock

CRON

Consensus forecasts updated

ACB

Consensus EPS estimates fall by 397%

FFNT

4Front Ventures Corp. to Report Q1, 2022 Results on May 23, 2022

GTII

Consensus EPS estimates fall by 12%

HITI

High Tide Inc. to Report Q2, 2022 Results on Jun 14, 2022

EPIC

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.011 loss in 2Q 2021)

GSD

High number of new directors